Agenus | AGEN - Pre Tax Profit


Agenus reported $-274.14M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Agenus USD -274.14M 80.46M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Celldex Therapeutics USD -67.04M 10.44M Sep/2025
CSL USD 1.4B 1.14B Jun/2025
Dynavax Technologies USD 28.42M 7.2M Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 482.31M 75.7M Sep/2025
Intrexon USD -60.48M 27.09M Jun/2024
J&J USD 4.97B 2.53B Dec/2025
Jiangsu Hengrui CNY 1.36B 1.61B Sep/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
MacroGenics USD 16.82M 52.97M Sep/2025
Merck EUR 1.29B 458.1M Sep/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Novavax USD -122.33M 286.92M Sep/2024
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 18.89M 17.64M Sep/2025